Walleye Capital LLC Raises Stake in Dynavax Technologies Corporation $DVAX

Walleye Capital LLC increased its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 50,734.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 266,879 shares of the biopharmaceutical company’s stock after purchasing an additional 266,354 shares during the period. Walleye Capital LLC owned 0.22% of Dynavax Technologies worth $3,461,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in DVAX. Envestnet Asset Management Inc. lifted its holdings in Dynavax Technologies by 20.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 2,796 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Dynavax Technologies during the 4th quarter worth about $192,000. First Trust Advisors LP purchased a new stake in Dynavax Technologies during the 4th quarter worth about $847,000. Dimensional Fund Advisors LP lifted its holdings in Dynavax Technologies by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock worth $51,948,000 after purchasing an additional 171,933 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in Dynavax Technologies by 5.3% during the 4th quarter. MetLife Investment Management LLC now owns 80,883 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 4,106 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX opened at $10.26 on Thursday. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -22.30 and a beta of 1.09. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. Dynavax Technologies Corporation has a 1-year low of $9.22 and a 1-year high of $14.63. The stock’s 50-day moving average is $10.61 and its 200 day moving average is $11.35.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. The company had revenue of $95.44 million for the quarter, compared to analysts’ expectations of $87.55 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. On average, sell-side analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.33.

Insider Buying and Selling

In related news, Director Scott Dunseth Myers purchased 3,800 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director directly owned 35,004 shares of the company’s stock, valued at approximately $378,743.28. This trade represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 2.98% of the stock is owned by company insiders.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.